MedPath

Budesonide as a treatment for inflammation in stomach complaints.

Phase 1
Conditions
Functional dyspepsia
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Registration Number
EUCTR2020-002593-27-BE
Lead Sponsor
Z Leuven
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
36
Inclusion Criteria

•Functional dyspepsia patients with meal related symptoms (postprandial distress syndrome) as described by the Rome IV criteria
•Patients aged between 18 and 70 years inclusive
•Male or female patients

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 31
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5

Exclusion Criteria

•Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable to participate in the study
•Patients with any major psychiatric disorders (including those with a major psychosomatic element to their gastrointestinal disease), depression, alcohol or substance abuse in the last 2 years
•Patients presenting with predominant symptoms of irritable bowel syndrome (IBS) or of gastro-esophageal reflux disease (GERD)
•Patients with diabetes mellitus, celiac disease, lupus, scleroderma or other systemic auto-immune disease
•Patients with eosinophilic esophagitis or eosinophilic gastroenteritis
•Patients with active H. Pylori infection (or < 6 months after eradication)
•Patients with proven food allergy
•Patients with an organic gastro-intestinal disease of history of gastrointestinal surgery other than appendectomy
•Patients with known sever impaired liver dysfunction
•Patients who take drugs altering gastric emptying, anti-inflammatory drugs, acid suppressive drugs or some drugs altering the CYP3A4 metabolism
•Patients with major change in diet in the last 3 months
•Females who are pregnant or lactating
•Patients not capable to understand or be compliant with the study.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath